TW200604184A - Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors - Google Patents

Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors

Info

Publication number: TW200604184A
Authority: TW; Taiwan
Prior art keywords: processes; kinase inhibitors; fused heterocyclic; intermediates useful; preparing fused
Prior art date: 2004-06-28

Application number

TW094121497A

Other languages

English (en)

Inventor

Gerard Crispino

Stephanie Barbosa

Jun-Ying Fan

Zhen-Wei Cai

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-28

Filing date

2005-06-27

Publication date

2006-02-01

2005-06-27 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2006-02-01 Publication of TW200604184A publication Critical patent/TW200604184A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Transplantation (AREA)

TW094121497A 2004-06-28 2005-06-27 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors TW200604184A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58345904P	2004-06-28	2004-06-28
US61256304P	2004-09-23	2004-09-23

Publications (1)

Publication Number	Publication Date
TW200604184A true TW200604184A (en)	2006-02-01

Family

ID=35457856

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW094121497A TW200604184A (en)	2004-06-28	2005-06-27	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW094121488A TW200607505A (en)	2004-06-28	2005-06-27	Fused heterocyclic kinase inhibitors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW094121488A TW200607505A (en)	2004-06-28	2005-06-27	Fused heterocyclic kinase inhibitors

Country Status (14)

Country	Link
US (2)	US20050288290A1 (zh)
EP (3)	EP1768983A2 (zh)
JP (3)	JP4782117B2 (zh)
KR (3)	KR20070026621A (zh)
AR (2)	AR049536A1 (zh)
AU (2)	AU2005259894C1 (zh)
BR (1)	BRPI0512722A (zh)
CA (1)	CA2571680A1 (zh)
IL (1)	IL180325A0 (zh)
MX (2)	MXPA06015192A (zh)
NO (3)	NO20070453L (zh)
PE (2)	PE20060374A1 (zh)
TW (2)	TW200604184A (zh)
WO (3)	WO2006004833A2 (zh)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7030112B2 (en) *	2003-03-25	2006-04-18	Bristol-Myers Squibb Company	Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US9169406B2 (en) *	2003-08-25	2015-10-27	Dow Global Technologies Llc	Coating compositions
WO2005030140A2 (en)	2003-09-26	2005-04-07	Exelixis, Inc.	C-met modulators and methods of use
DE10357510A1 (de) *	2003-12-09	2005-07-07	Bayer Healthcare Ag	Heteroarylsubstituierte Benzole
EP1719763A4 (en)	2004-02-27	2008-01-09	Eisai R&D Man Co Ltd	NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2)
WO2005095400A1 (en) *	2004-03-30	2005-10-13	Vertex Pharmaceuticals Incorporated	Azaindoles useful as inhibitors of jak and other protein kinases
DE102004017438A1 (de) *	2004-04-08	2005-11-03	Bayer Healthcare Ag	Hetaryloxy-substituierte Phenylaminopyrimidine
US7459562B2 (en) *	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) *	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US20050288290A1 (en) *	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) *	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
EP1773826A4 (en) *	2004-07-02	2009-06-03	Exelixis Inc	MODULATORS OF C-MET AND THEIR METHOD OF USE
CN101031570B (zh) *	2004-07-30	2012-09-05	梅特希尔基因公司	Vegf受体和hgf受体信号的抑制剂
US7504521B2 (en) *	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en)	2004-08-12	2006-12-12	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7569725B2 (en) *	2004-10-21	2009-08-04	Britsol-Myers Squibb Company	Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US8875040B2 (en) *	2005-06-07	2014-10-28	Rockwell Automation Technologies, Inc.	Universal web-based reprogramming method and system
TW200635927A (en) *	2004-12-22	2006-10-16	Bristol Myers Squibb Co	Synthetic process
AU2006229343A1 (en) *	2005-03-28	2006-10-05	Kirin Pharma Kabushiki Kaisha	Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
US7470693B2 (en) *	2005-04-21	2008-12-30	Bristol-Myers Squibb Company	Oxalamide derivatives as kinase inhibitors
JO2787B1 (en)	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
NZ563774A (en) *	2005-05-20	2010-04-30	Methylgene Inc	Inhibitors of VEGF receptor and HGF receptor signaling
KR101378716B1 (ko) *	2005-05-20	2014-04-10	메틸진 인코포레이티드	Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
US7405213B2 (en) *	2005-07-01	2008-07-29	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7232901B2 (en)	2005-07-01	2007-06-19	Bristol-Myers Squibb Company	Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7402582B2 (en) *	2005-07-01	2008-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
JP5072595B2 (ja) *	2005-08-05	2012-11-14	中外製薬株式会社	マルチキナーゼ阻害剤
WO2007023768A1 (ja)	2005-08-24	2007-03-01	Eisai R & D Management Co., Ltd.	新規ピリジン誘導体およびピリミジン誘導体（３）
US7732613B2 (en) *	2005-09-14	2010-06-08	Bristol-Myers Squibb Company	Met kinase inhibitors
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
CA2635888A1 (en) *	2006-01-04	2007-07-19	Locus Pharmaceuticals, Inc.	Inhibitors of protein kinases
RU2008139599A (ru) *	2006-03-07	2010-04-20	Эррэй Биофарма Инк. (Us)	Гетеробициклические производные пиразола и способы их применения
US20080064718A1 (en) *	2006-03-22	2008-03-13	Saavedra Oscar M	Inhibitors of protein tyrosine kinase activity
PT2010538E (pt) *	2006-04-21	2013-02-22	Bristol Myers Squibb Co	Processo para a preparação de éster 2-[4-(4-fluoro-2- metil-1h-indol-5-iloxi)-5-metilpirrolo[2,1-f][1,2,4]- triazin-6-iloxi]-1 -metiletílico do ácido [(1r), 2s]-2- aminopropiónico
TW200808763A (en)	2006-05-08	2008-02-16	Astrazeneca Ab	Novel compounds I
TW200808771A (en) *	2006-05-08	2008-02-16	Astrazeneca Ab	Novel compounds II
JP2009537632A (ja) *	2006-05-19	2009-10-29	バイエル・ヘルスケア・アクチェンゲゼルシャフト	過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体
JP2009539878A (ja) *	2006-06-08	2009-11-19	アレイバイオファーマ、インコーポレイテッド	キノリン化合物および使用方法
JP5642963B2 (ja) *	2006-06-30	2014-12-17	スネシスファーマシューティカルズ，インコーポレイティド	ピリジノニルｐｄｋ１阻害剤
ES2375284T3 (es) *	2006-08-23	2012-02-28	Eisai R&D Management Co., Ltd.	Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma.
US7790885B2 (en)	2006-08-31	2010-09-07	Eisai R&D Management Co., Ltd.	Process for preparing phenoxypyridine derivatives
US20080255155A1 (en) *	2006-10-18	2008-10-16	Stephane Raeppel	Kinase inhibitors and uses thereof
EP2079738A2 (en) *	2006-10-27	2009-07-22	Glaxo Group Limited	7-azaindole derivatives as c-met kinase inhibitors
CA2669266C (en) *	2006-11-08	2014-04-29	Bristol-Myers Squibb Company	Pyridinone compounds
WO2008116064A2 (en) *	2007-03-21	2008-09-25	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
CN105777776B (zh)	2007-08-29	2021-06-08	梅特希尔基因公司	蛋白酪氨酸激酶活性的抑制剂
ES2593279T3 (es)	2007-08-29	2016-12-07	Methylgene Inc.	Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados
DE102007051762A1 (de)	2007-10-30	2009-05-07	Bayer Healthcare Ag	Substituierte Pyrrolotriazine und ihre Verwendung
BRPI0819258A2 (pt)	2007-11-06	2017-05-02	Astrazeneca Ab	alguns derivados de 2-pirazinona e seu uso como inibidores da elastase neutrófila
WO2009061516A1 (en)	2007-11-08	2009-05-14	New York University School Of Medicine	Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
JP2009132660A (ja)	2007-11-30	2009-06-18	Eisai R & D Management Co Ltd	食道癌治療用組成物
HRP20130040T1 (hr) *	2008-01-23	2013-02-28	Bristol-Myers Squibb Company	4-piridinon spojevi i njihova uporaba kod karcinoma
WO2009094427A1 (en)	2008-01-23	2009-07-30	Bristol-Myers Squibb Company	4-pyridinone compounds and their use for cancer
UA100262C2 (uk) *	2008-03-05	2012-12-10	Метилген Інк.	Інгібітори активності протеїнтирозинкінази
EP2262498A2 (en) *	2008-03-10	2010-12-22	Vertex Pharmceuticals Incorporated	Pyrimidines and pyridines useful as inhibitors of protein kinases
UY31982A (es) *	2008-07-16	2010-02-26	Boehringer Ingelheim Int	Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
UY31984A (es) *	2008-07-16	2010-02-26	Boehringer Ingelheim Int	DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
TWI365185B (en)	2008-07-24	2012-06-01	Lilly Co Eli	Amidophenoxyindazoles useful as inhibitors of c-met
KR100961410B1 (ko) *	2008-10-14	2010-06-09	(주)네오팜	단백질 키나제 억제제로서 헤테로사이클릭 화합물
TW201035100A (en)	2008-12-19	2010-10-01	Cephalon Inc	Pyrrolotriazines as ALK and JAK2 inhibitors
DK2387563T4 (da)	2009-01-16	2022-07-18	Exelixis Inc	Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
TW201036957A (en) *	2009-02-20	2010-10-16	Astrazeneca Ab	Novel salt 628
US20120136033A1 (en) *	2009-05-18	2012-05-31	President And Fellows Of Harvard College	Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof
AU2010262905B2 (en)	2009-06-17	2015-04-16	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
KR20120089459A (ko)	2009-08-24	2012-08-10	에즈셉피온 파마슈티컬즈, 인코포레이티드	키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물
WO2011139891A1 (en)	2010-04-29	2011-11-10	Deciphera Pharmaceuticals, Llc	Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
ES2715611T3 (es)	2010-05-17	2019-06-05	Incozen Therapeutics Pvt Ltd	Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
CA2802644C (en)	2010-06-25	2017-02-21	Eisai R & D Management Co., Ltd.	Antitumor agent using compounds having kinase inhibitory effect in combination
EP2423208A1 (en)	2010-08-28	2012-02-29	Lead Discovery Center GmbH	Pharmaceutically active compounds as Axl inhibitors
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
AU2012294917A1 (en) *	2011-08-10	2014-03-20	Merck Patent Gmbh	Pyrido-pyrimidine derivatives
KR102164317B1 (ko)	2012-03-30	2020-10-13	리젠 파마슈티컬스 소시에떼 아노님	C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
TWI520962B (zh) *	2012-06-29	2016-02-11		As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
MX2015004979A (es)	2012-12-21	2015-07-17	Eisai R&D Man Co Ltd	Forma amorfa de derivado de quinolina y metodo para su produccion.
EP2948454B1 (en) *	2013-01-24	2017-05-31	Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860)	Triazine compounds and a process for preparation thereof
SG11201509278XA (en)	2013-05-14	2015-12-30	Eisai R&D Man Co Ltd	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
ES2683127T3 (es) *	2013-10-17	2018-09-25	Blueprint Medicines Corporation	Composiciones útiles para tratar trastornos relacionados con la KIT
EP3068782B1 (en)	2013-11-13	2018-05-23	Vertex Pharmaceuticals Incorporated	Methods of preparing inhibitors of influenza viruses replication
ES2741444T3 (es)	2013-11-13	2020-02-11	Vertex Pharma	Inhibidores de la replicación de virus de la gripe
EP3087070B1 (en) *	2013-12-26	2017-11-08	Ignyta, Inc.	Pyrazolo[1,5-a]pyridine derivatives and methods of their use
WO2016004305A2 (en)	2014-07-02	2016-01-07	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
IL302218B2 (en)	2014-08-28	2024-10-01	Eisai R&D Man Co Ltd	Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja)	2015-02-25	2020-11-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体の苦味抑制方法
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US10654808B2 (en)	2015-04-07	2020-05-19	Guangdong Raynovent Biotech Co., Ltd.	Tyrosine kinase inhibitor and pharmaceutical composition comprising same
WO2016183120A1 (en)	2015-05-13	2016-11-17	Vertex Pharmaceuticals Incorporated	Inhibitors of influenza viruses replication
WO2016183116A1 (en)	2015-05-13	2016-11-17	Vertex Pharmaceuticals Incorporated	Methods of preparing inhibitors of influenza viruses replication
EP3311841B1 (en)	2015-06-16	2021-07-28	PRISM BioLab Co., Ltd.	Anticancer agent
CN108135894B (zh)	2015-08-20	2021-02-19	卫材R&D管理有限公司	肿瘤治疗剂
EP3521276B1 (en) *	2016-09-30	2021-03-10	Guangdong Raynovent Biotech Co., Ltd.	Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
WO2018145525A1 (zh) *	2017-02-08	2018-08-16	中国医药研究开发中心有限公司	吡咯并芳杂环类化合物及其制备方法和医药用途
RU2750539C2 (ru)	2017-02-08	2021-06-29	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Фармацевтическая композиция для лечения опухоли
EP3583943B1 (en)	2017-02-15	2024-09-18	Taiho Pharmaceutical Co., Ltd.	Pharmaceutical composition
WO2018183712A1 (en)	2017-03-31	2018-10-04	Blueprint Medicines Corporation	Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
AU2018269996A1 (en)	2017-05-16	2019-11-21	Eisai R&D Management Co., Ltd.	Treatment of hepatocellular carcinoma
WO2018228923A1 (en) *	2017-06-13	2018-12-20	Bayer Pharma Aktiengesellschaft	Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
EP3655406A1 (en)	2017-07-18	2020-05-27	Bayer Pharma Aktiengesellschaft	Substituted pyrrolopyridine-derivatives
JP7074760B2 (ja)	2017-09-08	2022-05-24	大鵬薬品工業株式会社	抗腫瘍剤及び抗腫瘍効果増強剤
TWI842978B (zh) *	2018-07-13	2024-05-21	美商基利科學股份有限公司	衍生物
UY38349A (es)	2018-08-30	2020-03-31	Array Biopharma Inc	Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
EP3897630B1 (en)	2018-12-21	2024-01-10	Celgene Corporation	Thienopyridine inhibitors of ripk2
LT3856341T (lt)	2019-04-12	2023-12-27	Blueprint Medicines Corporation	(s)-1-(4-fluorfenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f] [1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amino kristalinės formos ir gamybos būdai
AU2020272743B2 (en)	2019-04-12	2025-10-16	Blueprint Medicines Corporation	Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases
CN110407839B (zh) *	2019-07-01	2022-01-04	江西科技师范大学	含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
US20220289679A1 (en) *	2019-07-29	2022-09-15	Takeda Pharmaceutical Company Limited	Heterocyclic compound
TWI872203B (zh) *	2020-02-14	2025-02-11	日商大鵬藥品工業股份有限公司	醯基硫脲化合物的製造方法
CN113880845A (zh) *	2021-10-13	2022-01-04	广州六顺生物科技股份有限公司	吡咯并三嗪衍生物及其制备方法和应用
EP4448492A1 (en) *	2021-12-17	2024-10-23	Reglagene, Inc.	Compositions and methods of making and using small molecules in the treatment of cancer
WO2024182556A1 (en)	2023-02-28	2024-09-06	Reglagene, Inc.	Compositions and methods for making and using small molecules for the treatment of health conditions

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3646202A (en)	1967-11-22	1972-02-29	Merck & Co Inc	Liver fluke compositions containing salicylic acid derivatives
JPS54115384A (en)	1978-02-28	1979-09-07	Hokko Chem Ind Co Ltd	Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides
CH648611A5 (de)	1980-08-18	1985-03-29	Staeubli Ag	Verfahren und schaftmaschine zur gleichstellung aller schaefte einer webmaschine.
GB2106500B (en)	1981-09-18	1986-01-02	Dow Chemical Co	Method for making benzoylphenylureas
DE3139457A1 (de)	1981-10-03	1983-04-21	Bayer Ag, 5090 Leverkusen	Neue substituierte benzanilidether, verfahren zu ihrer herstellung, ihre verwendung als fungizide und zwischenprodukte hierfuer
DE3464368D1 (de)	1983-03-09	1987-07-30	Beecham Group Plc	Anti-inflammatory pyrazolo pyridines
EP0151962A3 (en)	1984-01-25	1985-10-02	Beecham Group Plc	Pyrazolopyridine derivatives
US4663341A (en)	1984-02-16	1987-05-05	Rohm And Haas Company	Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides
GB8404584D0 (en)	1984-02-22	1984-03-28	Beecham Group Plc	Compounds
CH657015A5 (de)	1984-06-27	1986-08-15	Ciba Geigy Ag	Motten- und kaeferschutzmittel.
JPS6133176A (ja)	1984-07-24	1986-02-17	Ishihara Sangyo Kaisha Ltd	Ｎ−ニトロベンゾイル−ｎ’−ピリダジニルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する抗癌剤
US4753940A (en)	1985-02-15	1988-06-28	Ciba-Geigy Corporation	Barbituric acid derivatives
JPS62135463A (ja)	1985-12-09	1987-06-18	Ishihara Sangyo Kaisha Ltd	Ｎ−ベンゾイルウレア系化合物、それらを含有する抗癌剤並びにそれらの製造方法
JPS6262A (ja)	1986-03-05	1987-01-06	Ishihara Sangyo Kaisha Ltd	ベンゾイルウレア系化合物の製造方法
JPS625959A (ja)	1986-03-05	1987-01-12	Ishihara Sangyo Kaisha Ltd	ベンゾイルウレア系化合物
JPS625960A (ja)	1986-03-05	1987-01-12	Ishihara Sangyo Kaisha Ltd	ベンゾイルウレア系化合物の製造方法
US4908056A (en)	1986-04-25	1990-03-13	E. I. Du Pont De Nemours And Company	Heterocyclic acyl sulfonamides
DE3830054A1 (de)	1988-09-03	1990-03-15	Boehringer Mannheim Gmbh	Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5132315A (en) *	1989-05-19	1992-07-21	The United States Of America As Represented By The Department Of Health And Human Services	Therapeutic application of an anti-invasive compound
EP0420804A3 (en)	1989-09-26	1991-11-27	Ciba-Geigy Ag	Anthelmintic compounds
SU1761753A1 (ru)	1990-07-16	1992-09-15	Ф. С. Михайлицын и Н. С. Уварова	5-(2-Хлор-4-нитро(амино)фенокси) бензо-2,1,3-тиадиазол в качестве промежуточного соединени в синтезе 5- @ 2-хлор-4-[(2-окси-3,5-дибромбензоил)амино]фенокси @ бензо-2,1,3-тиадиазола, про вл ющего активность при гименолепидозе белых мышей
US5646176A (en)	1992-12-24	1997-07-08	Bristol-Myers Squibb Company	Phosphonooxymethyl ethers of taxane derivatives
US6214344B1 (en)	1995-06-02	2001-04-10	Genetech, Inc.	Hepatocyte growth factor receptor antagonists and uses thereof
AU7296896A (en) *	1995-11-01	1997-05-22	Novartis Ag	Purine derivatives and processes for their preparation
EP0860433B1 (en)	1995-11-07	2002-07-03	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
DE19710609A1 (de)	1997-03-14	1998-09-17	Bayer Ag	Substituierte Aminosalicylsäureamide
EP0994877A1 (en)	1997-07-03	2000-04-26	Du Pont Pharmaceuticals Company	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6022884A (en)	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
HUP0100287A3 (en) *	1997-11-11	2003-04-28	Pfizer Prod Inc	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6362369B2 (en)	1997-11-25	2002-03-26	Nihon Nohyaku Co., Ltd.	Phthalic acid diamide derivatives fluorine-containing aniline compounds as starting material, agricultural and horticultural insecticides, and a method for application of the insecticides
TW515786B (en)	1997-11-25	2003-01-01	Nihon Nohyaku Co Ltd	Phthalic acid diamide derivatives, agricultural and horticultural insecticides, and a method for application of the insecticides
ES2317688T3 (es)	1998-01-29	2009-04-16	Amgen Inc.	Moduladores ppar-gamma.
US6232320B1 (en) *	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
CZ299375B6 (cs)	1998-11-30	2008-07-09	Nihon Nohyaku Co., Ltd.	Ftalamidové deriváty nebo jejich soli, zemedelsko-zahradnický insekticid je obsahující a jeho použití
US20020065296A1 (en)	1999-01-13	2002-05-30	Bayer Corporation	Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
ATE253051T1 (de)	1999-01-22	2003-11-15	Kirin Brewery	Chinolinderivate und chinazolinderivate
ATE254615T1 (de)	1999-02-22	2003-12-15	Biotechnolog Forschung Gmbh	C-21 modifizierte epothilone
GB9904103D0 (en)	1999-02-24	1999-04-14	Zeneca Ltd	Quinoline derivatives
GB9906566D0 (en) *	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
US6982265B1 (en) *	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
WO2000071129A1 (en)	1999-05-21	2000-11-30	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
WO2000075145A1 (en)	1999-06-03	2000-12-14	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
ES2546386T3 (es)	1999-07-20	2015-09-23	Dow Agrosciences, Llc	Amidas aromáticas heterocíclicas fungicidas y sus composiciones, métodos de uso y preparación
US6355660B1 (en)	1999-07-20	2002-03-12	Dow Agrosciences Llc	Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
GB9918035D0 (en) *	1999-07-30	1999-09-29	Novartis Ag	Organic compounds
CZ20021009A3 (cs)	1999-09-21	2002-06-12	Astrazeneca Ab	Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
PL353791A1 (en)	1999-09-24	2003-12-01	Nihon Nohyaku Co, Ltd.Nihon Nohyaku Co, Ltd.	Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same
WO2001042243A2 (en)	1999-12-08	2001-06-14	Advanced Medicine, Inc.	Protein kinase inhibitors
AU2223201A (en)	1999-12-24	2001-07-09	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
US6750246B1 (en)	2000-02-03	2004-06-15	Bristol-Myers Squibb Company	C-4 carbonate taxanes
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DE60106022T2 (de)	2000-06-06	2006-03-09	Pfizer Products Inc., Groton	Thiophenverbindungen zur verwendung als antikrebsmittel
FR2812633A1 (fr)	2000-08-04	2002-02-08	Aventis Cropscience Sa	Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
WO2002032872A1 (fr)	2000-10-20	2002-04-25	Eisai Co., Ltd.	Composes a noyau aromatique azote
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
GEP20063915B (en)	2000-11-17	2006-09-11	Bristol Myers Squibb Co	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
EP1341771A2 (en)	2000-11-29	2003-09-10	Glaxo Group Limited	Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2002051397A1 (en)	2000-12-22	2002-07-04	Ishihara Sangyo Kaisha, Ltd.	Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
AU2002254152A1 (en) *	2001-03-08	2002-09-24	Millennium Pharmaceuticals	(homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US7081454B2 (en) *	2001-03-28	2006-07-25	Bristol-Myers Squibb Co.	Tyrosine kinase inhibitors
US6995171B2 (en)	2001-06-21	2006-02-07	Agouron Pharmaceuticals, Inc.	Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
KR100883731B1 (ko)	2001-06-22	2009-02-12	기린 파마 가부시끼가이샤	간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
SE0102384D0 (sv)	2001-07-03	2001-07-03	Pharmacia Ab	New compounds
WO2003011028A1 (fr)	2001-08-01	2003-02-13	Nissan Chemical Industries, Ltd.	Amides substitues et pesticides
EP1447405A4 (en)	2001-10-17	2005-01-12	Kirin Brewery	CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
CA2468716A1 (en) *	2001-11-28	2003-06-05	Fujisawa Pharmaceutical Co., Ltd.	Heterocyclic amide compounds as apolipoprotein b inhibitors
ES2400070T3 (es) *	2001-12-03	2013-04-05	Bayer Healthcare Llc	Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
JP2003321472A (ja)	2002-02-26	2003-11-11	Takeda Chem Ind Ltd	Ｇｒｋ阻害剤
US6900208B2 (en)	2002-03-28	2005-05-31	Bristol Myers Squibb Company	Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7388009B2 (en) *	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
ATE418546T1 (de) *	2002-04-23	2009-01-15	Bristol Myers Squibb Co	Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
HRP20040988A2 (en) *	2002-04-23	2005-06-30	Bristol-Myers Squibb Company A Delaware (Usa) Corp	Pyrrolo-triazine aniline compounds useful as kinas
TW200407143A (en)	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
TW200401638A (en)	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
AR040456A1 (es)	2002-06-27	2005-04-06	Bristol Myers Squibb Co	Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
TWI272271B (en) *	2002-07-19	2007-02-01	Bristol Myers Squibb Co	Process for preparing certain pyrrolotriazine compounds
AU2003265349A1 (en)	2002-08-02	2004-02-23	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7074810B2 (en)	2002-10-07	2006-07-11	Bristol-Myers Squibb Company	Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
CL2003002287A1 (es)	2002-11-25	2005-01-14	Wyeth Corp	COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
AR042486A1 (es)	2002-12-18	2005-06-22	Glaxo Group Ltd	Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
MXPA05008183A (es)	2003-02-05	2005-10-05	Bristol Myers Squibb Co	Proceso para preparar pirrolotriazina como inhibidores de cinasa.
US7030112B2 (en) *	2003-03-25	2006-04-18	Bristol-Myers Squibb Company	Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US20070213374A1 (en)	2003-07-07	2007-09-13	Merck Patent Gmbh	Malonamide Derivatives
JP2007504122A (ja)	2003-08-29	2007-03-01	ファイザー・インク	新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体
SE0302487D0 (sv)	2003-09-18	2003-09-18	Astrazeneca Ab	Novel compounds
WO2005030140A2 (en)	2003-09-26	2005-04-07	Exelixis, Inc.	C-met modulators and methods of use
US7419978B2 (en)	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
DE10357510A1 (de) *	2003-12-09	2005-07-07	Bayer Healthcare Ag	Heteroarylsubstituierte Benzole
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
EP1719763A4 (en)	2004-02-27	2008-01-09	Eisai R&D Man Co Ltd	NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2)
DE102004017438A1 (de)	2004-04-08	2005-11-03	Bayer Healthcare Ag	Hetaryloxy-substituierte Phenylaminopyrimidine
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) *	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) *	2004-06-09	2005-12-22	Pfizer Inc.	Ether-linked heteroaryl compounds
US7102002B2 (en) *	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7432373B2 (en) *	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) *	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
TW200600513A (en) *	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7504521B2 (en) *	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds

2005
- 2005-06-24 US US11/167,043 patent/US20050288290A1/en not_active Abandoned
- 2005-06-24 US US11/167,049 patent/US7173031B2/en not_active Expired - Lifetime
- 2005-06-27 TW TW094121497A patent/TW200604184A/zh unknown
- 2005-06-27 TW TW094121488A patent/TW200607505A/zh unknown
- 2005-06-28 EP EP05764291A patent/EP1768983A2/en not_active Withdrawn
- 2005-06-28 WO PCT/US2005/023099 patent/WO2006004833A2/en not_active Ceased
- 2005-06-28 JP JP2007519390A patent/JP4782117B2/ja not_active Expired - Fee Related
- 2005-06-28 JP JP2007519322A patent/JP4860609B2/ja not_active Expired - Fee Related
- 2005-06-28 JP JP2007519416A patent/JP2008504368A/ja not_active Withdrawn
- 2005-06-28 PE PE2005000752A patent/PE20060374A1/es not_active Application Discontinuation
- 2005-06-28 WO PCT/US2005/023198 patent/WO2006004884A2/en not_active Ceased
- 2005-06-28 KR KR1020067026897A patent/KR20070026621A/ko not_active Withdrawn
- 2005-06-28 EP EP05790229A patent/EP1771177A4/en not_active Withdrawn
- 2005-06-28 AR ARP050102668A patent/AR049536A1/es not_active Application Discontinuation
- 2005-06-28 KR KR1020067027376A patent/KR20070028458A/ko not_active Ceased
- 2005-06-28 AR ARP050102669A patent/AR050254A1/es not_active Application Discontinuation
- 2005-06-28 WO PCT/US2005/022682 patent/WO2006004636A2/en not_active Ceased
- 2005-06-28 BR BRPI0512722-0A patent/BRPI0512722A/pt not_active Application Discontinuation
- 2005-06-28 MX MXPA06015192A patent/MXPA06015192A/es active IP Right Grant
- 2005-06-28 EP EP05791275A patent/EP1761268A4/en not_active Withdrawn
- 2005-06-28 PE PE2005000754A patent/PE20060524A1/es not_active Application Discontinuation
- 2005-06-28 MX MXPA06015032A patent/MXPA06015032A/es not_active Application Discontinuation
- 2005-06-28 AU AU2005259894A patent/AU2005259894C1/en not_active Ceased
- 2005-06-28 KR KR1020067027370A patent/KR20070037448A/ko not_active Ceased
- 2005-06-28 CA CA002571680A patent/CA2571680A1/en not_active Abandoned
- 2005-06-28 AU AU2005260056A patent/AU2005260056B2/en not_active Ceased
2006
- 2006-12-25 IL IL180325A patent/IL180325A0/en unknown
2007
- 2007-01-24 NO NO20070453A patent/NO20070453L/no not_active Application Discontinuation
- 2007-01-26 NO NO20070514A patent/NO20070514L/no not_active Application Discontinuation
- 2007-01-26 NO NO20070506A patent/NO20070506L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20060004006A1 (en)	2006-01-05
EP1768983A2 (en)	2007-04-04
NO20070514L (no)	2007-03-12
PE20060374A1 (es)	2006-05-07
JP2008504367A (ja)	2008-02-14
CA2571680A1 (en)	2006-01-12
WO2006004884A2 (en)	2006-01-12
AU2005260056B2 (en)	2009-08-27
KR20070026621A (ko)	2007-03-08
AR049536A1 (es)	2006-08-09
WO2006004636A2 (en)	2006-01-12
US7173031B2 (en)	2007-02-06
AR050254A1 (es)	2006-10-11
KR20070028458A (ko)	2007-03-12
JP2008504368A (ja)	2008-02-14
EP1771177A2 (en)	2007-04-11
NO20070506L (no)	2007-02-14
US20050288290A1 (en)	2005-12-29
NO20070453L (no)	2007-01-24
AU2005259894C1 (en)	2009-09-17
WO2006004636A3 (en)	2006-05-26
AU2005260056A1 (en)	2006-01-12
BRPI0512722A (pt)	2008-04-01
KR20070037448A (ko)	2007-04-04
AU2005259894A1 (en)	2006-01-12
WO2006004833A2 (en)	2006-01-12
JP2008504366A (ja)	2008-02-14
IL180325A0 (en)	2007-07-04
EP1761268A4 (en)	2009-07-08
JP4860609B2 (ja)	2012-01-25
MXPA06015032A (es)	2007-02-08
JP4782117B2 (ja)	2011-09-28
TW200607505A (en)	2006-03-01
EP1761268A2 (en)	2007-03-14
EP1771177A4 (en)	2009-07-29
MXPA06015192A (es)	2007-02-28
PE20060524A1 (es)	2006-06-21
WO2006004884A3 (en)	2006-03-23
WO2006004833A3 (en)	2006-07-13
AU2005259894B2 (en)	2009-03-19

Publication	Publication Date	Title
TW200604184A (en)	2006-02-01	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
IN2009DN05670A (zh)	2015-07-24
TW200640924A (en)	2006-12-01	VEGF-R2 inhibitors and methods
GB2453058A (en)	2009-03-25	Kinase antagonists
EA200970738A1 (ru)	2010-06-30	Ингибиторы активности akt
IL163781A0 (en)	2005-12-18	Purine derivatives as kinase inhibitors
PL1682530T3 (pl)	2007-09-28	Podstawione pirolo-indole jako inhibitory PAI-1
GEP20094785B (en)	2009-09-25	Pyrrolopyrazoles, potent kinase inhibitors
MXPA05013553A (es)	2006-03-09	Pirrolodihidroisoquinolinas como inhibidores de pde10.
TW200732349A (en)	2007-09-01	Anti-OX40L antibodies and methods using same
PT1761520E (pt)	2008-09-15	Inibidores de quinase
TNSN07196A1 (en)	2008-11-21	Potentiators of glutamate receptors
TW200624426A (en)	2006-07-16	BACE inhibitors
MX2011001679A (es)	2011-12-16	Derivados de flavina.
TNSN08191A1 (en)	2009-10-30	Kinase inhibitors
IL176142A0 (en)	2006-10-05	Processes for preparing montelukast sodium
TW200728277A (en)	2007-08-01	Bicyclic derivatives as P38 inhibitors
UA107689C2 (xx)	2015-02-10	ПОХІДНІ 3,4,4A,10B-ТЕТРАГІДРО-1H-ТІОПІРАНО$4, 3-c]ІЗОХІНОЛІНУ
WO2006034113A3 (en)	2006-08-24	Quinolone analogs as cell proliferation inhibitors
TW200738751A (en)	2007-10-16	Anti-EphrinB2 antibodies and methods using same
MY142105A (en)	2010-09-15	Leukotriene biosynthesis inhibitors
TW200619206A (en)	2006-06-16	Chemokine-binding heterocyclic compound salts, and methods of use thereof
UA85505C2 (en)	2009-01-26	Kinase inhibitors
WO2007146813A3 (en)	2008-03-06	Pyridinone analogs as cell proliferation inhibitors
MX2008001538A (es)	2008-04-04	Aril piridinas y metodos para su uso.